

**Table 1: Utilization of the facility** (provide the total number of users that have utilized the facility by institution)

| Institution                      | # Of Users |
|----------------------------------|------------|
| University of Texas at Dallas    | 4          |
| University of Texas Southwestern | 5          |

**Table 2: Additional/Follow-On Funding** (provide information in Table 2 about the funding source, type of funder, grant ID, title of grant, total amount received (direct plus indirect costs over the entire performance period), total project period of investment/award, a description of the subject of the funding, PI of the grant, and PI's organization.

| Funding Source | Type of Funder     | Award ID    | Title of Grant                         | Total Amount Received (Direct and Indirect Costs for All Years) | Total Project Period of Investment/Award | Investment/Award Description  | PI       | PI Organization     |
|----------------|--------------------|-------------|--|---|--|---|----------|---------------------|
| NIH            | Federal Government | R01 CA12345 | Molecular Epidemiology of Cancer Cells | \$1,000,000   | 09 Jun 2021- 08 Jun 2023                 | This project aims to characterize the molecular epidemiology of cancer cells. | John Doe | University of Texas |

**Table 3: Publications citing the facility** Enter information about each publication in the table. Information includes PubMed ID, author, title, journal, and publication date.

| PubMed ID | Authors                               | Title                                    | Journal     | Publication Date |
|-----------|---------------------------------------|--|-------------|------------------|
| 12345     | Doe, JD, Doe, JN, Smith, DM, Smith, T | Identification of p53 as a cancer driver | Cancer Cell | 2021 Jun 15      |
|           |                                       |  |             |                  |

**Table 4: Clinical trials supported by the facility** Enter trial name, clinicaltrials.gov identifier, clinical research categories (interventional and observational), primary purpose, primary anatomic cancer site, phase, clinical trial focus, clinical trial site, and patients enrolled.

| Trial Name                        | Clinicaltrials.gov ID | Clinical Research Category | Primary Purpose* | Primary Anatomic Cancer Site | Phase    | Trial Focus** | Trial Site          | Total Number of Patients Accrued to Date |
|-----------------------------------|-----------------------|----------------------------|------------------|------------------------------|----------|---------------|---------------------|--|
| TCC: Targeting Cancer Cells Study | NCT01234              | Interventional             | Treatment        | Leukemias                    | Phase II | Drug-Biologic | University of Texas | 100                                      |

\***Primary Purpose categories:** Basic Science, Diagnostic, Health Services Research, Prevention, Screening, Supportive Care, Treatment.

\*\* **Trial Focus categories:** Bank Study, Biological-Other, Cell Therapy, Devices, Diagnostics, Drug-Biologic, Drug-Small Molecule, Immunotherapy, Procedures, Vaccine, Other.

**Table 5: Filed/granted patents resulting from research supported by the facility** Enter patent number, inventors, patent title, description, date of publication or issue, and date the patent application was filed and/or granted.

| Patent Number | Inventors                          | Patent Title                                  | Description                                       | Date of Publication or Issue | Date of Patent Filed and/or granted |
|---------------|------------------------------------|---|---|------------------------------|-------------------------------------|
| 12/345, 678   | Doe, John; Doe, Jane, Smith, David | Receptor Inhibitors and Methods of Use Therof | Potent receptor inhibitors that reduce tumor size | 17 Dec 2020                  | 17 Dec 2019                         |